Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Amedeo Ferdinando CapettiGiuseppe Vittorio De SocioMaria V CossuGaetana SterrantinoGiovanni CenderelloAnnamaria CattelanGianmaria BaldinAlessandro SoriaNiccolò RiccardiFosca P NieroBenedetto M CelesiaGiorgio BarbariniStefano RusconiGiuliano RizzardiniPublished in: HIV clinical trials (2019)
These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.